MA56536A - Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) - Google Patents

Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)

Info

Publication number
MA56536A
MA56536A MA056536A MA56536A MA56536A MA 56536 A MA56536 A MA 56536A MA 056536 A MA056536 A MA 056536A MA 56536 A MA56536 A MA 56536A MA 56536 A MA56536 A MA 56536A
Authority
MA
Morocco
Prior art keywords
hbv
liposomes
hepatitis
virus
administration
Prior art date
Application number
MA056536A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Ian Strickland
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56536A publication Critical patent/MA56536A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056536A 2019-06-20 2020-06-19 Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) MA56536A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863958P 2019-06-20 2019-06-20

Publications (1)

Publication Number Publication Date
MA56536A true MA56536A (fr) 2022-04-27

Family

ID=71833365

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056536A MA56536A (fr) 2019-06-20 2020-06-19 Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)

Country Status (7)

Country Link
US (1) US20220305108A1 (fr)
EP (1) EP3986563A1 (fr)
AU (1) AU2020295807A1 (fr)
CA (1) CA3143631A1 (fr)
MA (1) MA56536A (fr)
TW (1) TW202114732A (fr)
WO (1) WO2020255062A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120456919A (zh) * 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
CH624011A5 (fr) 1977-08-05 1981-07-15 Battelle Memorial Institute
CH621479A5 (fr) 1977-08-05 1981-02-13 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CN101291653B (zh) 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
EP1729848B1 (fr) 2004-03-08 2015-04-29 Ichor Medical Systems Inc. Appareil ameliore pour une administration electriquement mediee d'agents therapeutiques
EP1766035B1 (fr) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Arn interferant encapsule dans des lipides
CA2666501C (fr) 2006-10-17 2017-03-21 Vgx Pharmaceuticals, Inc. Dispositifs d'electroporation et leurs procedes d'utilisation pour l'electroporation de cellules de mammiferes
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
DK2590676T3 (en) * 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
WO2016020538A1 (fr) * 2014-08-08 2016-02-11 Transgene Sa Traitement en association d'un vaccin contre le hbv et d'un anticorps pour traiter des infections à hbv.
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
CN114085198A (zh) 2015-06-29 2022-02-25 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
US9962449B2 (en) 2015-07-31 2018-05-08 Arcturus Therapeutics, Inc. MultiLigand agent for drug delivery
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US9834510B2 (en) * 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
WO2017117528A1 (fr) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipides et formulations de nanoparticules de lipides pour la libération d'acides nucléiques
KR102535764B1 (ko) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 치료제를 전달하기 위한 장치
WO2018119163A1 (fr) 2016-12-21 2018-06-28 Payne Joseph E Lipide cationique ionisable pour l'administration d'arn
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018191657A1 (fr) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipides pour administration d'agents actifs
WO2018199338A1 (fr) * 2017-04-27 2018-11-01 国立大学法人広島大学 Molécule d'acide nucléique pour le traitement de l'hépatite b
WO2018200943A1 (fr) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Nouveaux lipides carbonyles et formulations nanoparticulaires lipidiques pour l'administration d'acides nucléiques
WO2019036008A1 (fr) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
WO2019036030A1 (fr) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques
WO2019036028A1 (fr) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019051257A2 (fr) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation Méthodes de traitement des infections de type hépatite b
US11021692B2 (en) * 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof

Also Published As

Publication number Publication date
CA3143631A1 (fr) 2020-12-24
WO2020255062A1 (fr) 2020-12-24
US20220305108A1 (en) 2022-09-29
TW202114732A (zh) 2021-04-16
AU2020295807A1 (en) 2022-02-17
EP3986563A1 (fr) 2022-04-27

Similar Documents

Publication Publication Date Title
WO2017027350A3 (fr) Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
MA50278A (fr) Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
JOP20170161B1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3710049A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb
MY154683A (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
JOP20180003B1 (ar) عوامل RNAi ألفا-1 مضادة للتريبسين (AAT)، وتركيبات تتضمن عوامل AAT RNAi، وطرق الاستخدام
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
JP2020531422A5 (fr)
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
WO2017019891A3 (fr) Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
SG10201900695PA (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
HRP20201953T1 (hr) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
NZ628445A (en) Antiviral compounds with a heterotricycle moiety
CL2007002490A1 (es) Metodos para el tratamiento de un huesped vivo que tiene una infeccion por el virus de hepatitis c; composicion para el tratamiento de la infeccion por hepatitis c; y un producto de elaboracion para la administracion de terapia combinada para el trat
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
EP2940133A4 (fr) Vaccin contre l'infection par le hpv et/ou l'hépatite b contenant une protéine hpv/hbs chimérique à titre de principe actif
JP2019510064A5 (fr)
MA56536A (fr) Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
MY202118A (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
SG11201811516QA (en) Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof